Links to publications that use this peptide:
Chen et al. Dynorphin peptides differentially regulate the human kappa opioid receptor
Life Sci. 2007 Mar 20;80(15):1439-48.
Chen et al. Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists.
J Pharmacol Exp Ther. 2006 Nov;319(2):765-75.
Wang et al. Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation.
J Pharmacol Exp Ther. 2003 Dec;307(3):1127-34.
Li et al. Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human kappa opioid receptor by enhancing its recycling rate.
J Biol Chem. 2002 Jul 26;277(30):27545-52.
Liu et al. Femtomolar Concentrations of Dynorphins Protect Rat Mesencephalic Dopaminergic Neurons against Inflammatory Damage
J Pharmacol Exp Ther. 2001 Sep;298(3):1133-41.
Yakovleva et al. p53 Latency. C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences.
J Biol Chem. 2001 May 11;276(19):15650-8.
For best results and reproducibility, rehydrate peptide just before use. Do not attempt to weigh out smaller portions. Do not refreeze any unused portions.